Podcasts about therapeutics

Therapeutics, vaccines, Regeneron, will therapeutics replace vaccines?, the biotechnology industry, genetic engineering, Stanford, University of California at San Francisco (UCSF), the roll of the Bay area in biotech, advances in gene editing during the 1990s, mRNA and its links to therapeutics, Jesse Gelsinger, Bush II and bans on research, lipid nanoparticles (LNPs), the advent of synthetic biology, cell therapy, stem cells, embryonic stem cell controversy, CRISPR, CRISPR CaS9, Jennifer Dounda, Emmanuelle Cherpentier, Feng Zhang, Broad Institute, UC Berkeley, Intellia Therapeutics, CRISPR Therapeutics, Operation Warp Speed, Editas Medicine, Innovative Genomics Institute (IGI), Covid vaccines, why the Covid vaccines are more like a therapeutic, AI biotech, AlphaFold2, tech money piles into biotech post pandemic, Arc Institute, Vitalik Buterin, Big Pharma and its lack of involvement in therapeutics, Big Tech's entry into defense and healthcare, Peter Thiel, Thiel as the catalyst for modern therapeutic research, life-extension, Thiel's extensive investment in therapeutics and biotech, Jason Camm, Jim Mellon, Brexit, Thiel's lack of investment in CRISPRResourcesTrump on "miracle drugs":https://www.yahoo.com/news/article/trump-coronavirus-twitter-video-234914108.html?guccounter=1On the links between therapeutics and the Covid vaccineshttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02444-3/fulltexthttps://pmc.ncbi.nlm.nih.gov/articles/PMC12179814/AI Biotechhttps://whatisbiotechnology.org/index.php/science/summary/aiBig Tech and AI biotechhttps://www.forbes.com/sites/richardnieva/2024/03/13/why-nvidia-google-and-microsoft-are-betting-billions-on-biotechs-ai-future/How funding for biotech has unfolded since the 2010shttps://www.fiercebiotech.com/biotech/how-healthy-exchange-ideas-rfk-jr-kicked-fdas-gene-therapy-pushThiel's Links to Biotechhttps://www.technologyreview.com/2015/03/16/168909/a-contrarian-in-biotech/https://sociallifemagazine.com/celebrities/bezos-thiel-longevity-investments/https://www.inc.com/jeff-bercovici/emerald-therapeutics-peter-thiel.htmlhttps://www.fiercebiotech.com/biotech/thiel-s-breakout-labs-fuels-four-new-life-science-companieshttps://alloytx.com/42-million-series-d-financing/https://www.wholesaleinvestor.com/epiaxis-therapeutics-peter-thiel-backed-peptilogics-enter-strategic-partnership/https://www.businessinsider.com/peter-thiel-funded-de-extinction-animal-resurrection-woolly-mammoth-2017-6https://www.sfgate.com/tech/article/synthego-after-raising-forced-bankrupcty-20331773.phpJason Camm's biohttps://www.berentx.com/companyMusic by: Keith Allen Dennishttps://keithallendennis.bandcamp.com/ Hosted on Acast. See acast.com/privacy for more information.

Is fat good or bad for your heart? For decades, we blamed fat and cholesterol for clogged arteries and heart attacks. Now you choose low-fat yogurt to protect your heart, while others cook with beef tallow. In this episode, Dr. Alice Lichtenstein, a world-leading expert on dietary fat and heart health, helps settle the debate. Dr. Lichtenstein explains which fats protect your heart and which to cut back on, you'll learn what raises your cholesterol, and why the type of fat you eat matters more than how much of it you eat. You'll leave the episode with some practical food swaps to protect your heart and live longer. Have you swapped butter for "low-fat" alternatives loaded with sugar? Could that choice be working against your heart?

Send us a text if you want to be on the Podcast & explain why!Read the article here on Showupfitness.com: https://www.showupfitness.com/blogs/blog/chronic-tendon-pain-why-load-beats-rest-and-what-shockwave-actually-doesThat nagging Achilles that “felt better with rest” and then flared the second you returned to training isn't bad luck, and it usually isn't an inflammation problem you can ice away. Chronic tendon pain is often a capacity problem, which means the fix is not doing less forever, it's rebuilding tolerance with the right load, the right timeline, and the right rules.We read a detailed article from Dr. Rob, a physical therapist and clinic owner, and translate it into practical coaching for personal trainers. We break down what tendinopathy actually looks like in chronic cases, why the old “tendinitis” model leads people into months of stop-start training, and how the pain monitoring model gives you guardrails without demanding zero discomfort. The centerpiece is the 24-hour rule: judge your dosage by how the tendon feels tomorrow, not just how it feels mid-set.From there, we lay out a four-stage tendon rehab and return-to-sport framework you can run with cleared clients: isometrics for high irritability, heavy slow resistance as the main tendon remodeling tool, energy storage work for running and jumping, and a smart return to the real demand while keeping strength work in the plan. We also call out common trainer mistakes, the importance of upstream strength, and the specific red flags that mean you stop and refer out.We finish by getting honest about shockwave therapy (ESWT): what it is, where evidence is strongest, and why it never builds tendon capacity on its own. If you want more confident programming, better outcomes, and a stronger PT referral network, subscribe, share this with a trainer friend, and leave a review.Want to become a SUCCESSFUL personal trainer? SUF-CPT is the FASTEST growing personal training certification in the world!Want to ask us a question?  Email info@showupfitness.com with the subject line PODCAST QUESTION to get your question answered live on the show!Website: https://www.showupfitness.com/Become a Successful Personal Trainer Book Vol. 2 (Amazon): https://a.co/d/1aoRnqANASM / ACE / ISSA study guide: https://www.showupfitness.com

What if the chemistry created by neurological disease could help activate medicine precisely where it is needed? In this episode of Tech Talks Daily, I speak with Sara Isbell, neuroscientist and co-founder of Enabled Therapeutics, about a proposed approach to one of medicine's most stubborn problems: delivering effective drugs to diseased brain tissue without exposing healthy areas to the same activity. Sara explains how the blood-brain barrier prevents many promising compounds from reaching the brain. When drugs do enter, they may spread across healthy and diseased regions alike, creating a difficult balance between therapeutic benefit and unwanted effects. We hear how an unexpected laboratory result led Sara and her co-founder to investigate whether pathological oxidative stress could convert a precursor molecule into a biologically active compound near the affected tissue. Sara describes this as pathology-gated therapeutic activation, where disease-associated chemistry provides the trigger that turns the medicine on. This remains developing science. At the time of recording, Enabled Therapeutics was preparing its first peer-reviewed manuscript and seeking partners to support further studies. Sara explains why reproducible evidence, regulatory guidance, and careful laboratory validation must determine whether the hypothesis advances. We also discuss how AI helps small biotechnology teams review literature, organize regulatory materials, connect ideas across scientific disciplines, and identify possible hypotheses. However, Sara offers an important reminder: AI can propose possibilities, but nature and experimental evidence decide what is true. Could following one unexpected result eventually offer researchers another way to approach neurological disease? Listen to the conversation and share your thoughts with me.

Michael Remole, MA, LCPC, NCC, I/ECHMHC, is a clinician, speaker, author, and consultant with more than 20 years of experience specializing in trauma and the neuroscience of healing. He is the founder and CEO of Gateway Family Services of ois, where he integrates the Neurosequential Model of Therapeutics and Natzural Lifemanship's Trauma-Focused Equine Assisted Psychotherapy to provide innovative, individualized care. A Phase III/Mentor within the Neurosequential Network, Michael also serves as a trainer and consultant, contributing to the advancement of trauma-informed practice locally, nationally, and internationally. He is the co-founder of 4R Refuge and a contributing author to The Handbook for Children with Complex Trauma and Dissociation.Dr. Emily Wang is a clinical psychologist with more than 30 years of experience in mental health and currently serves as Senior Director of Clinical Advancement and Trauma-Informed Practice at Hull Services. A Fellow of the Neurosequential Model Network and a specialist in Infant-Parent Mental Health, she has trained and consulted extensively on the impact of trauma on child development for educators, clinicians, caregivers, and Indigenous communities. Dr. Wang is also an Adjunct Lecturer at the University of Calgary's Cumming School of Medicine and is actively involved in research on child maltreatment and mental health. She is the recipient of the 2020 Bruce D. Perry Spirit of the Child Award and the 2023 Psychologist's Association of Alberta Psychologist of the Year Award.In This EpisodeMichael Remole's WebsiteGateway Family ServicesHull ServicesPathways To Prevention SymposiumBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-trauma-therapist--5739761/support.---Thank you to our Sponsors: Jane App - use code GUY1MO at https://janesoftware.partnerlinks.io/ngvcwcxqt2jx-4afv8i (https://jane.app/book_a_demo)Beducated - Complete the quiz for one month free https://beduc.at/pd2633-traumatherapist

Julia Kang-Reeves shares her story with Dr. Stephanie J. Wong of immigrating from Seoul to NY. She later spent nearly two decades in London, raising her daughter who attended all-female schools until returning to the US. From learning to navigate various cultures to becoming the CMO of wellness company, Earth Therapeutics to co-lead the family business, Earth Therapeutics, Julia shares the challenges and joys of a multi-dimensional identity.  Bio ========================================== Julia co-leads the 30-year-old company alongside her brother John Kang (Founder & CEO) — a brand he launched in 1993 as an offshoot of the family's business after leaving a budding law career. With virtually no skin-care experience at the time, John began selling loofah sponges to Bed Bath & Beyond — one of the first to introduce the loofah to the U.S. market and laying the foundation for what would become a category-defining wellness brand. Together, Julia and John have continued building on the entrepreneurial spirit of their immigrant parents, who remain actively involved and still come into the office — a daily reminder that the company is rooted in family, resilience, and long-term relationships. Earth Therapeutics went on to help pioneer both the early natural body care movement and the rise of Korean spa (K-spa) beauty stateside — long before "wellness" became a marketing buzzword. A classicist-turned-writer-turned-CMO, Julia studied Classics at the University of Chicago and Columbia (where she received a Presidential Fellowship) before earning an MFA in Fiction Writing at NYU. After nearly two decades in London, she returned in 2020 to help lead her family's brand into a new era. Having grown up alongside the original '90s natural products movement — long before "wellness" became a buzzword — she now brings that long-view perspective to a Gen Z world shaped by burnout, trend cycles, and social media pressure. She believes America doesn't have a beauty crisis — it has a health crisis (including mental health). And she's leading a brand focused on function, ritual, and longevity over hype.

How have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to discuss the evolution of monoclonal antibody therapeutics and their experiences with shaping—and documenting—the field. Their conversation covers the advances that have transformed the industry, evolving success rates for antibody therapeutics, and the growing sophistication of multispecific antibodies, antibody-drug conjugates, and more. Plus, they discuss both AI and China's emergence as major forces in antibody development. Links from this episode:  Genentech mAbs 

A clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Welcome to the latest On the Couch. In this episode I am catching up with Chris Burns,  the CEO and MD of Amplia Therapeutics (ATX).Chris is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 25 years.   He has a Ph.D. from the University of Melbourne and is the inventor on over 30 patents and a co-author on over 60 scientific publications. He was co-recipient of the 2024 Prime Minister's Prize for Innovation and is a Fellow of the Australian Academy of Health and Medical Sciences, the Royal Society of Chemistry (UK) and the Royal Australian Chemical Institute.   Dr Burns was originally appointed as a Non-Executive Director on 4 May 2018 and was subsequently appointed as Chief Executive Officer and Managing Director on 5 December 2022.Amplia Therapeutics Limited (ATX) is an Australian, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.​

Lew Bender, Founder and CEO of Intensity Therapeutics, has developed a novel approach to treating solid tumors through direct intratumoral injection of existing chemotherapy drugs. The company uses a proprietary formulation containing a special molecule that makes water-based drugs soluble in fatty tissue, allowing cisplatin and vinblastine to penetrate tumor cells effectively. Beyond direct killing of cancer cells, the approach triggers an immunological response that trains the immune system to recognize and attack cancer cells throughout the body, including metastatic tumors that were not directly injected. Lew explains, "We're injecting directly into the tumors, and we have identified a formulation that allows for water-based drugs to become soluble in fat and water. Effectively, a tumor is fat and water. And while it has been tried before to inject water into fat, I helped to develop a chemistry that allows for water-based products to be absorbed by fatty tissue like tumors." "We are injecting our formulation, which is a special molecule called SHAO, that makes things soluble in fat and water, and two very well-known potent anti-cancer agents, cisplatin and vinblastine, that are able to kill cancers when they get into the cancer cells. So we dose based on the size of the tumor, check into the tumors, and the tumors in an immunological way. So what does that mean? It means that as the tumor cells die, they create chemicals that allow for the influx and recognition of the immune cells that this is not a good entity to be in the body." "We are killing the cancer with the drug, but at the same time training the immune system on the tumors so that the immune system can recognize the cancer as not self and attack the cancer in a more precise way." #IntensityTherapeutics $INTS  #CancerResearch #Oncology #Biotech #CancerCare  #ClinicalTrials #BreastCancer #TargetedOncology #IntratumoralInjection #OncologyInnovation #ImmunoOncology #IntratumoralTherapy #SolidTumors #TNBC #Sarcoma #HealthcareProfessionals intensitytherapeutics.com Download the transcript here

Lew Bender, Founder and CEO of Intensity Therapeutics, has developed a novel approach to treating solid tumors through direct intratumoral injection of existing chemotherapy drugs. The company uses a proprietary formulation containing a special molecule that makes water-based drugs soluble in fatty tissue, allowing cisplatin and vinblastine to penetrate tumor cells effectively. Beyond direct killing of cancer cells, the approach triggers an immunological response that trains the immune system to recognize and attack cancer cells throughout the body, including metastatic tumors that were not directly injected. Lew explains, "We're injecting directly into the tumors, and we have identified a formulation that allows for water-based drugs to become soluble in fat and water. Effectively, a tumor is fat and water. And while it has been tried before to inject water into fat, I helped to develop a chemistry that allows for water-based products to be absorbed by fatty tissue like tumors." "We are injecting our formulation, which is a special molecule called SHAO, that makes things soluble in fat and water, and two very well-known potent anti-cancer agents, cisplatin and vinblastine, that are able to kill cancers when they get into the cancer cells. So we dose based on the size of the tumor, check into the tumors, and the tumors in an immunological way. So what does that mean? It means that as the tumor cells die, they create chemicals that allow for the influx and recognition of the immune cells that this is not a good entity to be in the body." "We are killing the cancer with the drug, but at the same time training the immune system on the tumors so that the immune system can recognize the cancer as not self and attack the cancer in a more precise way." #IntensityTherapeutics $INTS  #CancerResearch #Oncology #Biotech #CancerCare  #ClinicalTrials #BreastCancer #TargetedOncology #IntratumoralInjection #OncologyInnovation #ImmunoOncology #IntratumoralTherapy #SolidTumors #TNBC #Sarcoma #HealthcareProfessionals intensitytherapeutics.com Listen to the podcast here

In this week's episode of the Xtalks Life Science Podcast, host Soumya Shashikumar, Senior Life Sciences Journalist at Xtalks, spoke with James Mackay, CEO of Crystalys Therapeutics, about gout, persistent misconceptions surrounding the condition and current clinical research. Gout is often linked primarily to diet and alcohol. James explains that many patients instead have difficulty removing enough uric acid from the body, allowing crystals to accumulate in the joints and contribute to inflammation over time. The conversation examines the stigma this misunderstanding can create. James shares why some people may avoid discussing their condition or seeking care because they feel blamed for developing it. He also discusses difficult-to-treat gout, the limitations of current treatment options and how researchers are studying outcomes that may be more meaningful to patients. Tune in to learn more about why gout remains widely misunderstood, the gaps in current care and the challenges of developing treatments for patients with limited options. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Episode 146 – Clonidine   Welcome to the first in a little duo of episodes on oral alpha 2 agonists. This week, I'll be talking about clonidine, and next week, I'm going to talk about guanfacine – another oral alpha 2 agonist – and compare and contrast the 2 for you in terms of use and indications. Clonidine is a really useful psychopharmacological agent that is quite commonly used as both an event medication as well as a daily adjunct to baseline medications.   So, I thought we'd do a bit of a deep dive into clonidine and the things you, as professionals, need to know about this medication.   Here's what you'll learn: ·         Indications for and uses of clonidine as both an event- and a daily adjunctive medication in Veterinary Behaviour Medicine. ·         Why clonidine might be a good choice for hyper-aroused, hyper-active and hyper-vigilant patients. ·         When clonidine might be a better choice than guanfacine. ·         Potential drug interactions and contraindications.   Here are the 2 published papers I mention in the episode: Ogata, N. and Dodman, N.H., 2011. The use of clonidine in the treatment of fear-based behavior problems in dogs: an open trial. Journal of Veterinary Behavior, 6(2), pp.130-137.   Pflaum, K., Albright, J., Cox, S. and Smith, J., 2026. Pharmacokinetics of Orally Administered Clonidine in Dogs. Journal of Veterinary Pharmacology and Therapeutics.   This is a bit of a whistlestop tour into clonidine, but if you'd like to dive even deeper, I've got you covered – My PSYCHOACTIVE course contains everything you need to know: https://katrin-jahn.mykajabi.com/psychoactive   And here is the Professional Guides E-Book I mention in the episode, which includes a handout about clonidine: https://katrin-jahn.mykajabi.com/trinity-ebook   If you liked this episode of the show, Veterinary Behaviour Chat, please LEAVE A 5-STAR REVIEW, like, share, and subscribe!   Facebook Group: Join The Veterinary Behaviour Community on Facebook   You can CONNECT with me: Website: Visit my website Trinity Veterinary Behaviour Instagram: Follow Trinity Veterinary Behaviour on Instagram Trinity Veterinary Behaviour Facebook: Join us on Trinity Veterinary Behaviour's Facebook page Trinity Veterinary Behaviour YouTube: Subscribe to Trinity Veterinary Behaviour on YouTube LinkedIn Profile: Connect with me on LinkedIn   Thank you for tuning in!

We love to hear from our listeners. Send us a message.Episode 134 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Shannon Boye, PhD, Founder and CSO of Atsena Therapeutics. Dr. Boye shares how the company is approaching Stargardt disease with a differentiated gene therapy strategy built around delivery, dual-vector design, and a disciplined go/no-go framework. Their conversation also explores what Atsena's broader clinical experience is teaching the team as it advances new programs and works toward the clinic.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

WisBusiness: the Podcast with Goutham Narla, WARF Therapeutics by wispolitics

Jerry Avorn is a professor of medicine at Harvard Medical School and the codirector of the Program on Regulation, Therapeutics, and Law at Harvard Medical School and Brigham and Women's Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J. Avorn. Products That Pose Health Risks — Can Litigation Protect Us When Government Fails? N Engl J Med 2026;395:421-423.

Lance Baldo, CEO of Beacon Therapeutics, shares his insights about leadership in biopharma and how Beacon is working to save and restore sight for people living with rare and prevalent ocular diseases.

Nate Stasko, CEO of Vast Therapeutics, is developing a novel nitric oxide-releasing therapy to treat chronic respiratory diseases, particularly fibrosis bronchiectasis, which is frequently misdiagnosed as asthma or COPD. Their lead drug candidate is a dual-mechanism therapy that is delivered to the lungs via a nebulizer to target both infection and inflammation with the potential to eradicate pathogens rather than just suppressing them. This approach, in early trials, is showing excellent tolerability and eliminates the need for chronic antibiotic use, which carries the risks of toxicity and contributes to antibiotic resistance.  Nate explains, "At Vast Therapeutics, our main idea and goal as a company is to come up with better solutions for the 500 million people worldwide who suffer from chronic respiratory disease. And there is a new disease getting a lot of attention that we're targeting with our lead program called bronchiectasis, and it's often been misdiagnosed as asthma or COPD. And now over a million patients in the US are being diagnosed with bronchiectasis. And the whole campaign is to teach physicians and the whole medical community to suspect this disease over some of these other misdiagnosed diseases."  "Traditionally, patients have been managed with either antibiotics to calm down the infection, but you know the problems of chronic antibiotic use- the liver toxicity, kidney toxicity, and hearing loss associated with long-term antibiotic use are just bad for these patients. Not to mention we have the global problem of antibiotic resistance. And so giving a 52-week course of therapy of antibiotics is less than ideal. And then recently, just last year, there's some hope for these patients where there was a new drug approved called brensocatib, which was the first drug ever approved for bronchiectasis by the FDA. And so now it targets the inflammation." "Having the ability to target two mechanisms of action would be the best therapy. And that's actually what Vast is developing. We're using the body's own ability to make and produce nitric oxide, which is a miracle molecule. And we're delivering nitric oxide back to these patients to target both the infection and inflammation at the same time and improve the overall standard of care for these patients."  #VastTherapeutics #Bronchiectasis #Pulmonology #NitricOxide #RespiratoryMedicine #AntimicrobialResistance #ALX1#ChronicLungDisease #HealthcareInnovation #ClinicalTrials vasttherapeutics.com Download the transcript here

Nate Stasko, CEO of Vast Therapeutics, is developing a novel nitric oxide-releasing therapy to treat chronic respiratory diseases, particularly fibrosis bronchiectasis, which is frequently misdiagnosed as asthma or COPD. Their lead drug candidate is a dual-mechanism therapy that is delivered to the lungs via a nebulizer to target both infection and inflammation with the potential to eradicate pathogens rather than just suppressing them. This approach, in early trials, is showing excellent tolerability and eliminates the need for chronic antibiotic use, which carries the risks of toxicity and contributes to antibiotic resistance.  Nate explains, "At Vast Therapeutics, our main idea and goal as a company is to come up with better solutions for the 500 million people worldwide who suffer from chronic respiratory disease. And there is a new disease getting a lot of attention that we're targeting with our lead program called bronchiectasis, and it's often been misdiagnosed as asthma or COPD. And now over a million patients in the US are being diagnosed with bronchiectasis. And the whole campaign is to teach physicians and the whole medical community to suspect this disease over some of these other misdiagnosed diseases."  "Traditionally, patients have been managed with either antibiotics to calm down the infection, but you know the problems of chronic antibiotic use- the liver toxicity, kidney toxicity, and hearing loss associated with long-term antibiotic use are just bad for these patients. Not to mention we have the global problem of antibiotic resistance. And so giving a 52-week course of therapy of antibiotics is less than ideal. And then recently, just last year, there's some hope for these patients where there was a new drug approved called brensocatib, which was the first drug ever approved for bronchiectasis by the FDA. And so now it targets the inflammation." "Having the ability to target two mechanisms of action would be the best therapy. And that's actually what Vast is developing. We're using the body's own ability to make and produce nitric oxide, which is a miracle molecule. And we're delivering nitric oxide back to these patients to target both the infection and inflammation at the same time and improve the overall standard of care for these patients."  #VastTherapeutics #Bronchiectasis #Pulmonology #NitricOxide #RespiratoryMedicine #AntimicrobialResistance #ALX1#ChronicLungDisease #HealthcareInnovation #ClinicalTrials vasttherapeutics.com Listen to the podcast here

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape. Starting with some exciting news, Scribe Therapeutics has successfully closed its initial public offering, raising a significant $129 million. This substantial funding will drive forward their pioneering work in gene editing technologies, particularly focusing on therapies for cardiovascular diseases and atherosclerotic cardiovascular disease (ASCVD). By leveraging CRISPR technology, Scribe Therapeutics is positioned at the forefront of developing transformative treatments for both rare and common diseases. This advancement could potentially revolutionize how these conditions are managed, offering new hope for patients worldwide. On the regulatory front, Amgen is actively working to maintain its competitive edge in the U.S. market by submitting a comprehensive data package to the FDA for its drug Tavneos. This strategic move highlights the competitive nature of the pharmaceutical landscape where maintaining market access and drug positioning is crucial. Additionally, an FDA panel has recently endorsed lifting restrictions on four peptides, a decision that could significantly enhance therapeutic options in wound healing and autoimmune diseases through compounding pharmacies. This shift indicates a broader acceptance of peptides' therapeutic potential, which are increasingly being explored for their targeted therapy applications. In clinical trial news, Meiji Seika Pharma has reached a significant milestone with its combination therapy involving HBI-8000 and nivolumab. The therapy has successfully met the progression-free survival endpoint in a Phase 3 trial for advanced melanoma. This approach combines an epigenetic immunomodulator with a PD-1 inhibitor, representing a strategic method to harness immune system modulation for cancer treatment. Such advancements highlight ongoing innovations within oncology therapeutics and emphasize opportunities for improved patient outcomes through novel treatment combinations. However, not all clinical trials meet success. Sanofi's recent decision to halt Phase 3 development of amlitelimab for atopic dermatitis due to insufficient data serves as a reminder of the inherent challenges in drug development. Similarly, Ipsen's Bylvay did not meet its primary endpoint in a pivotal trial for biliary atresia patients post-Kasai surgery. These setbacks highlight the complexities involved in translating scientific discoveries into viable therapeutic options and underscore the unpredictable nature of drug development. Shifting to corporate strategies, Roche has decided to discontinue its development of an obesity asset, acmopatide, while placing support behind another candidate, enicepatide. This decision reflects dynamic prioritization within pipelines as companies navigate scientific data alongside market demands. Meanwhile, Fresenius has launched a €200 million corporate venture capital fund targeting innovations across biopharma, medtech, and digital care sectors. This move aligns with an increasing trend towards supporting early-stage innovations addressing unmet medical needs. In mergers and acquisitions news, Scancell's acquisition of Neophoria Therapeutics via reverse merger showcases strategic maneuvers within the sector aimed at securing financial stability and market presence through listings such as on NASDAQ. These activities illustrate broader industry trends where companies seek growth through strategic partnerships and acquisitions to enhance technological capabilities and market reach. In oncology developments, GSK has achieved a landmark FDA approval for Jideytro following its acquisition of Nuvalent. This milestone underscores the strategic importance of mergers and acquisitions in achieving rapid growth and diversification in oncology pipelines. The quick payoff from this deal highlights how targeted acquisitions can accelerate therapeutic advancements. Turning our attention to HIV prevention strategies, Merck is expanding access to its investigational PrEP pill Alimatravir through voluntary licensing agreements even before regulatory approval. This proactive strategy mirrors Gilead's successful model and emphasizes the industry's shift towards accessibility and patient-centric approaches. Finally, technological advancements continue reshaping industry practices with AI integration into incentive compensation models being explored by companies like Novartis in collaboration with consulting firms such as ZS Associates. These efforts are part of a larger digital transformation within the industry aimed at enhancing operational efficiency and decision-making processes. As we wrap up today's insights, it's clear that these developments highlight an era where scientific innovation intersects with strategic business decisions and regulatory frameworks. The implications for patient care are profound as these efforts translate into more effective therapies with potential impacts on treatment accessibility, efficacy, and personalization. As the industry continues to evolve rapidly amidst scientific breakthroughs and regulatory changes, maintaining a balance between innovation, regulation, and market dynamics will be crucial for sustaining growth and improving health outcomes globally.Support the show

Grazia Aleppo, MD, discusses the evolving role of continuous glucose monitoring (CGM) in non-insulin-treated Type 2 diabetes, drawing from her recent review published in Diabetes Technology and Therapeutics that examines evolving evidence and real world implications.Practical considerations for integrating CGM into routine care are also reviewed, with an emphasis on early intervention and data-driven decision-making.Key Topics• Evidence supporting CGM use in non-insulin-treated type 2 diabetes • Limitations of A1C and the role of time in range • Impact of CGM on patient engagement and self-management • Clinical and real-world outcomes associated with CGM adoption • Practical applications for endocrinology and primary careLearn more about Northwestern Medicine Endocrinology 

We love to hear from our listeners. Send us a message.Episode 133 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Aprea Therapeutics' CEO, Dr. Oren Gilad. They cover the evolution of precision oncology, the science of synthetic lethality, and how Aprea is developing next-generation therapies that target cancer's unique genetic vulnerabilities while improving safety and efficacy. Dr. Gilad also shares insights into biomarker-driven drug development, where precision medicine is headed as researchers pursue more effective treatments for patients with difficult-to-treat solid tumors, and more.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Dyne Therapeutics is an early-stage company gearing up for its first launch, promising to tackle unmet need in patients with neuromuscular disease. President and CEO John Cox outlines the science behind the company's ambitions, and the expansion efforts that will support its metamorphosis from early-stage company to fully-fledged biotech.Key Points• Dyne Therapeutics is pioneering a new delivery method for its products targeting neuromuscular disease.• With two launches planned, the business is preparing to transform from early-stage company to fully-integrated biotech.• Shared clinical and commercial pathways for Dyne's primary disease areas allow for capital investment efficiencies.Introductions [00:06]Host Joe Coletti introduces John Cox, President and CEO of Dyne Therapeutics, a clinical-stage biotechnology company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.Dyne's journey to commercialization [00:47]Dyne spent 2025 validating its delivery platform. In 2026 it aims to transform itself from an early-stage to a commercial company, with its first product launch scheduled for 2027. Novel drug delivery method [02:09]While most genetic therapies approved for use in the past 10 years have been delivered to the liver, Dyne's technology is designed to deliver direct to the muscle and the central nervous system.Evidence of effectiveness [03:37]The technology allows for higher-than-typical dosage, but with a favorable safety profile. Trials are showing an improvement in function from baseline for patients with Duchenne muscular dystrophy and myotonic dystrophy.Capabilities and capital investment [06:22]The company is drafting in new capabilities to prepare for product launches. With $900m on the balance sheet, it is well capitalized. Its disease areas share the same clinical and commercial pathways, allowing for efficient capital allocation.

Marina Better is a PhD candidate in Physiology, Pharmacology, and Therapeutics (formerly Pharmacology and Molecular Sciences) at Johns Hopkins University whose research focuses on maternal-fetal health, drug delivery, and translational therapeutics for pregnancy-related conditions. Her work explores innovative nanomedicine and drug delivery approaches to improve outcomes in preterm birth and reproductive health. Originally from Fayetteville, Marina began her scientific journey as an NIH-RISE and NSF-PrOMiSS scholar at Fayetteville State University before continuing her training at Johns Hopkins. She has authored multiple peer-reviewed publications, presented her research nationally and internationally, and is deeply committed to mentorship, scientific equity, and expanding opportunities for underrepresented students in biomedical research. The long-term goal of Marina's work is to improve maternal and fetal health through interdisciplinary research and innovation.linkedin.com/in/marina-better-10935b14b?utm_source=share_via&utm_content=profile&utm_medium=member_iosPresented to you by The No Static Network!

In this episode, Lisa welcomes Jess Draper, a holistic infant occupational therapist, IBCLC, and pelvic floor therapist based in Eugene, Oregon. Through her practice, Hali'a Therapeutics, Jess provides concierge-style care for families from pregnancy through the first year of life, bringing a whole-body, nervous-system-informed lens to feeding, oral motor function, movement, milestones, and tongue tie care.Lisa and Jess talk about the important role occupational therapy can play in infant feeding and tongue tie care, especially when babies are struggling with regulation, sensory processing, oral motor coordination, head shape, or feeding patterns that do not fit neatly into one category.Jess explains sensory processing in a practical way, including how babies take in, filter, and respond to touch, sound, movement, and oral input. They discuss how sensory differences may show up during feeding, such as gagging, popping on and off the breast, difficulty reorganizing after switching sides, or becoming easily overwhelmed by movement, sound, or touch.They also explore neuroplasticity, mirror neurons, and why babies often need support learning how to use new tongue mobility after release. Jess shares why infant care should include more than identifying restriction, and why supporting function, movement, and nervous system regulation can make such a difference.The conversation also includes an important discussion about head shape, palate shape, birth positioning, time in containers, and how the body's structure can influence feeding. Lisa and Jess emphasize the importance of looking at the whole baby, not just the mouth.Lisa and Jess discuss:How occupational therapy fits into infant feeding and tongue tie careWhat sensory processing means in babiesSigns that sensory overwhelm may be affecting feedingWhy some babies struggle with oral input, movement, or switching sidesNeuroplasticity, mirror neurons, and infant oral motor learningWhy babies may need help learning to use new tongue mobilityHow head shape and palate shape can affect feedingThe impact of birth positioning, prematurity, and time in containersWhy whole-body assessment matters before and after tongue tie releaseSupporting both baby and parent as a connected dyadConnect with Jess DraperInstagram: @haliatherapeuticsEmail: jess@haliaot.comMore from Tongue Tie ExpertsExplore additional resources, including downloads, free guides, and links mentioned in this episode—along with access to our courses and new book:

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping our industry, starting with a significant regulatory milestone. Vera Therapeutics recently achieved FDA accelerated approval for Trutakna, a groundbreaking treatment for IgA nephropathy. This approval not only provides new hope for patients suffering from this chronic kidney disease but also highlights the innovative approach targeting APRIL and BAFF pathways, crucial in immune system regulation. The drug's accelerated approval is particularly noteworthy as it offers earlier access to promising therapies while further trials solidify its benefits. This positions Vera Therapeutics against industry giants like Novartis and Otsuka in nephrology therapeutics, highlighting the competitive landscape within this sector. The FDA's expedited pathways are increasingly facilitating quicker access to life-saving drugs, aligning regulatory processes with scientific advancements to address unmet medical needs. The spotlight on fusion proteins in tackling autoimmune and renal disorders could signal a broader trend in therapeutic development. In parallel, AstraZeneca has made waves by entering into a major licensing agreement with Sino Biopharmaceutical for their COPD candidate TQC3721. This $1.9 billion deal, with a $200 million upfront payment, exemplifies how global collaborations are becoming pivotal in expanding market reach. By focusing on respiratory diseases, AstraZeneca is strategically positioning itself to enhance treatment options for COPD patients worldwide, reflecting an industry-wide movement towards leveraging regional expertise in drug commercialization. Meanwhile, Evonik's $100 million investment in an Indiana API manufacturing plant marks a strategic effort to bolster domestic production capacities post-pandemic. This investment underscores the rising demand for Contract Development and Manufacturing Organization (CDMO) services, emphasizing supply chain resilience—an increasingly critical factor as biotech firms seek reliable production partners. On the clinical trial front, Satellos Bioscience has reported promising Phase 1 data for SAT-3247, its Duchenne muscular dystrophy candidate. This AAK1 inhibitor demonstrates potential in promoting muscle regeneration, a development that could significantly alter treatment paradigms for this progressive neuromuscular disorder. If further trials confirm these findings, it could revolutionize therapeutic approaches for rare diseases. Financially, Leo Cancer Care's recent $65 million Series D funding is set to advance its upright radiotherapy treatment system. Such innovations aim to improve precision and outcomes in cancer therapy, at the intersection of technology and patient care. Similarly, MeiraGTx's securing of up to $400 million from Oberland Capital underlines ongoing confidence in gene therapies targeting rare ophthalmological conditions. Strategic maneuvers continue to reshape industry landscapes with mergers like that of Caidya and Simbec-Orion forming a global CRO platform aimed at enhancing research capabilities across oncology and rare diseases. Such consolidations reflect broader trends towards operational efficiencies and scaling research capabilities globally. Amidst these developments, quality control remains paramount as evidenced by Amgen's recall of its heart failure drug due to quality concerns. Such challenges reiterate the importance of stringent quality assurance throughout production processes in safeguarding patient safety. Vertex's acquisition of Crinetics for $10 billion marks another strategic expansion into "white space blockbuster opportunities," illustrating how M&A activity is driving companies to bolster pipelines and capitalize on emerging scientific advancements. These developments collectively underscore the dynamic nature of the pharmaceutical and biotech industries as they navigate complex regulatory landscapes, financial recalibrations, and scientific breakthroughs. As companies strive towards more effective and accessible treatments across various therapeutic areas, their ability to adapt to these challenges remains crucial in shaping the future of healthcare delivery. Thank you for tuning into Pharma Daily. Stay informed with us as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

Financials surging as investors countdown to second quarter bank earnings next week, expecting major growth. The traders break down what the results could mean for these names and whether banks will see major gains. Then, shares of Kymera Therapeutics soaring as its Eczema drug trial timeline moves faster than expected. The firm's founder, president and CEO Nello Mainolfi talks trial data and where the company is heading next. Plus, SpaceX stock plummeting despite bull calls on the Street, the media market under pressure, and Coke hitting all-time highs back to its century-old IPO. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us Fan MailFor decades, cancer treatment has rested on three pillars: surgery, chemotherapy, and external beam radiation. A fourth is now taking shape, and it is drawing billions in investment from some of the largest pharmaceutical companies in the world.John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, joins host David E. Williams to explain how targeted radiotherapeutics pair a tumor-seeking molecule with a radioactive payload, delivering radiation to cancer cells while sparing healthy tissue. He also unpacks what Pluvicto's success in prostate cancer signals for the future of radioligand therapy.

Zach Henderson, CEO at MindMaze Therapeutics, has designed a precision neurotherapeutic solution designed to offer a scalable, engaging and immersive platform for patients recovering from strokes or managing Parkinson's disease. The solution is deployed across the entire care continuum from hospital to the patient's home, providing high-intensity therapy during the neuroplastic window. The emphasis is on augmenting therapists' care by equipping them with tools to encourage therapy adherence and with data to deliver precise, personalized care. Zach explains, "So at a very high level, there are millions and millions of people across the neurology spectrum who need this type of neuro rehabilitation, neurotherapeutic solutions, either with a therapist or without, but there are only so many therapists to go around. So there's a massive supply-demand imbalance that frankly cannot be, despite the efforts of the great therapists out there, it can never be filled without resorting to technology. And that's the exact gap that we're trying to fill in the marketplace."   "So MindMaze Therapeutics has a suite of solutions that are deployed across the whole continuum of care. So from acute care to the hospital to inpatient rehabilitation facilities, IRFs, to long-term acute care, to skilled nursing facilities, to outpatient, and all the way even patients taking the technology home. And then in that way, we're meeting the patient wherever they may happen to be. We're supporting the health system around the world. And importantly, we're giving therapy in this important neuroelastic window, which, in some studies, is the first 90 days following, say, a stroke, and in other studies, it goes all the way up to six months. And we're helping the health systems around the world scale their ability to treat even more patients at a very high and even improved rate." #MindMaze #ParkinsonsDisease #DigitalHealth #Neuroplasticity #PrecisionMedicine #Physiatry #Neurology #PhysicalTherapy #OccupationalTherapy #RehabInnovation #HealthTech MindMazeTherapeutics.com Download the transcript here

Zach Henderson, CEO at MindMaze Therapeutics, has designed a precision neurotherapeutic solution designed to offer a scalable, engaging and immersive platform for patients recovering from strokes or managing Parkinson's disease. The solution is deployed across the entire care continuum from hospital to the patient's home, providing high-intensity therapy during the neuroplastic window. The emphasis is on augmenting therapists' care by equipping them with tools to encourage therapy adherence and with data to deliver precise, personalized care. Zach explains, "So at a very high level, there are millions and millions of people across the neurology spectrum who need this type of neuro rehabilitation, neurotherapeutic solutions, either with a therapist or without, but there are only so many therapists to go around. So there's a massive supply-demand imbalance that frankly cannot be, despite the efforts of the great therapists out there, it can never be filled without resorting to technology. And that's the exact gap that we're trying to fill in the marketplace."   "So MindMaze Therapeutics has a suite of solutions that are deployed across the whole continuum of care. So from acute care to the hospital to inpatient rehabilitation facilities, IRFs, to long-term acute care, to skilled nursing facilities, to outpatient, and all the way even patients taking the technology home. And then in that way, we're meeting the patient wherever they may happen to be. We're supporting the health system around the world. And importantly, we're giving therapy in this important neuroelastic window, which, in some studies, is the first 90 days following, say, a stroke, and in other studies, it goes all the way up to six months. And we're helping the health systems around the world scale their ability to treat even more patients at a very high and even improved rate." #MindMaze #ParkinsonsDisease #DigitalHealth #Neuroplasticity #PrecisionMedicine #Physiatry #Neurology #PhysicalTherapy #OccupationalTherapy #RehabInnovation #HealthTech MindMazeTherapeutics.com Listen to the podcast here

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer's drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale. Sandrock shares his current thinking on the amyloid vs. beta debate (it's likely both) in Alzheimer's disease treatment, the role of emerging tools like fluid biomarkers in diagnosis and prevention, and why small biotechs take bigger risks than big pharma.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Guests:Martin Wikelski, Director at the Max Planck Institute of Animal BehaviorAndrea Kwakowsky, Associate Professor of Pharmacology & Therapeutics at the University of Galway

On today's episode, we welcome Dr. Stephanie Venn-Watson, Co-Founder and Co-CEO of Seraphina Therapeutics, the company behind Fatty15. Stephanie is a veterinary epidemiologist, author of The Longevity Nutrient, and one of the world's leading experts on C15:0 — the first essential fatty acid discovered in over 90 years. Stephanie's story starts in an unexpected place: studying aging Navy dolphins. While working to improve their long-term health, she and her team discovered C15:0, a fatty acid that may play a critical role in strengthening cells and supporting healthy aging. That discovery led to years of research, more than 100 peer-reviewed studies, dozens of patents, and ultimately Fatty15 — a science-backed supplement designed to support cellular health, longevity, and overall wellness. In this episode, Stephanie shares how a breakthrough in dolphin health became a human health innovation, why she believes we have misunderstood certain saturated fats for decades, and what consumers should know about C15:0, cellular fragility, and healthy aging. We also talk about building trust in the crowded wellness space, turning serious science into a consumer brand, and why some of the biggest discoveries come from questioning what everyone assumes is true. This episode is a must listen!   Are you interested in sponsoring and advertising on The Kara Goldin Show, which is now in the Top 1% of Entrepreneur podcasts in the world? Let me know by contacting me at karagoldin@gmail.com. You can also find me @‌KaraGoldin on all networks.   To learn more about Dr. Stephanie Venn-Watson and Fatty15:https://www.linkedin.com/in/stephanievennwatson/https://www.instagram.com/fatty15/https://www.fatty15.com/   Sponsored By: AT&T Business - Switch to AT&T Business at business.att.com Zocdoc - Go to Zocdoc.com/KARA to find and instantly book a doctor you love today. RULA - Go to Rula.com/KARAGOLDIN for convenient therapy that's covered by insurance. LinkedIn Jobs - Head to LinkedIn.com/KaraGoldin to post your job for free.   Check out our website to view this episode's show notes: https://karagoldin.com/podcast/856

Selena Freisens, Head of Global Medical Affairs at Merz Therapeutics, is focused on increasing access to tools to support neurological health. They have developed a digital app iFlexo, which is designed to provide at-home physiotherapy for stroke survivors.  The app has been tested in Nigeria and Sierra Leone in partnership with the World Stroke Organization and is designed to operate offline as well, to serve users in rural areas with limited internet connectivity. Selena explains, "Our company is family-owned and in its fifth generation, so we have a rather long-term legacy, and the newer part is Merz Therapeutics, and our focus in Merz Therapeutics is on neuroscience. So we practically cover the number of movement disorders such as Spasms, Dystonias. We also have a focus on Parkinson's and Multiple Sclerosis."   "We continuously work on building this awareness and knowledge. One example is Parkinson's disease. And when I started working with Parkinson's disease, most of the patients would have off episodes, which are exacerbations of their symptoms, but many of these off episodes are underdiagnosed, and they're not really treated optimally. So it's really a lot of attention is needed to educate not only HCPs and, of course, some other stakeholders, but particularly patients."   "So the time also matters for stroke survivors. So it's very important that they start as soon as possible all the therapies, but also the physiotherapy at the same time. What this digital tool does is give two options. One is education on the one side, and on the other hand, a guided exercise that will enable people and stroke survivors to exercise at home. And with that, obviously, the personalized goals have been worked out together with the experts and HCPs so that they can achieve those goals faster, while working from home." #MerzTherapeutics #StrokeRehab #DigitalHealth #NeuroRehab #AccessToHealth #WorldStrokeOrganization #Physiotherapy #HealthEquity #TeleRehab #HCPs #Africafirst #AccesstoHealth #EquitableAccess #PostStrokeRehabilitation #PatientDrivenInnovation Merztherapeutics.com Download the transcript here

Selena Freisens, Head of Global Medical Affairs at Merz Therapeutics, is focused on increasing access to tools to support neurological health. They have developed a digital app iFlexo, which is designed to provide at-home physiotherapy for stroke survivors.  The app has been tested in Nigeria and Sierra Leone in partnership with the World Stroke Organization and is designed to operate offline as well, to serve users in rural areas with limited internet connectivity. Selena explains, "Our company is family-owned and in its fifth generation, so we have a rather long-term legacy, and the newer part is Merz Therapeutics, and our focus in Merz Therapeutics is on neuroscience. So we practically cover the number of movement disorders such as Spasms, Dystonias. We also have a focus on Parkinson's and Multiple Sclerosis."   "We continuously work on building this awareness and knowledge. One example is Parkinson's disease. And when I started working with Parkinson's disease, most of the patients would have off episodes, which are exacerbations of their symptoms, but many of these off episodes are underdiagnosed, and they're not really treated optimally. So it's really a lot of attention is needed to educate not only HCPs and, of course, some other stakeholders, but particularly patients."   "So the time also matters for stroke survivors. So it's very important that they start as soon as possible all the therapies, but also the physiotherapy at the same time. What this digital tool does is give two options. One is education on the one side, and on the other hand, a guided exercise that will enable people and stroke survivors to exercise at home. And with that, obviously, the personalized goals have been worked out together with the experts and HCPs so that they can achieve those goals faster, while working from home." #MerzTherapeutics #StrokeRehab #DigitalHealth #NeuroRehab #AccessToHealth #WorldStrokeOrganization #Physiotherapy #HealthEquity #TeleRehab #HCPs #Africafirst #AccesstoHealth #EquitableAccess #PostStrokeRehabilitation #PatientDrivenInnovation Merztherapeutics.com Listen to the podcast here

References Cell Death & Disease 2018. v. 9, Article number: 600CNS Neuroscience & Therapeutics 2009. 15:32–51Oncol Lett 2016 Aug;12(2):897-903.Cell Death Discovery  2025V 11, Article number: 489 Biomedicine & Pharmacotherapy2024 v. 172, March 116229Guerra, DJ. 2026. Unpublished Lectures.Lennon/McCartney.1968. I'm So Tired. White Album-Beatleshttps://open.spotify.com/track/2X9H5BokS1u5O46YpNYNsZ?si=bdcc11350bc24d90Dubin/Warren. 1935.Lullaby of Broadway -Doris Day.(1951).https://open.spotify.com/track/4hG3Xgm6H4ELBi8ESQoosr?si=b5a84bdc0be84dbc

David Stamler, M.D., Chief Executive Officer AlterityTherapeuticsAlterity Therapeutics (NASDAQ: ATHE & ASX: ATH)www.alteritytx.com  David Stamler, M.D., Chief Executive OfficerDavid Stamler, M.D. is Chief Executive Officer and a Managing Director, and previously served as Alterity's Chief Medical Officer and Senior Vice President, Clinical Development. Dr Stamler has extensive drug development expertise spanning early-stage research through late-stage clinical trials, with three FDA drug approvals in neurology.Prior to joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals where he was Chief Medical Officer.Prior to Auspex, he served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., and Head of Drug Development at Prestwick Pharmaceuticals, Inc. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division.Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

Messenger RNA (mRNA) plays a literally central role in the functioning of life as we know it, shuttling information back and forth between the DNA where it is stored to the ribosome where it is used to produce proteins. RNA may even have been the first molecule to kick-start the origin of life. Today, scientists are learning how to manipulate mRNA to cure and prevent diseases, whether through vaccination or literally editing one's DNA. Jeff Coller explains how it all works and how mRNA is revolutionizing medicine as we know it. Blog post with transcript: https://www.preposterousuniverse.com/podcast/2026/06/15/357-jeff-coller-on-mrna-vaccines-and-bespoke-therapeutics/ Support Mindscape on Patreon. Jeff Coller received his Ph.D. in cell and molecular biology from the University of Wisconsin-Madison. He is currently Bloomberg Distinguished Professor of Biomedical Engineering and Director of the RNA Innovation Center at Johns Hopkins University. He is co-founder of Tevard Biosciences and the Alliance for mRNA Medicines, and leads the REPAIRx consortium. He is a fellow of the American Association for the Advancement of Science. Web site Johns Hopkins web page Google Scholar publications "This May Be the Most Important Medical Story of the Decade," New York Times, April 9, 2026

We love to hear from our listeners. Send us a message.In Episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast, Ascidian Therapeutics' Founder, President, and CEO Mike Ehlers, M.D., Ph.D., explains how the company is advancing a new class of genetic medicines built on RNA exon editing to durably correct disease at the transcript level without permanently altering DNA. He also shares why in vivo therapies still need to prove precision, durability, and predictability before they become mainstream, and why the field must move beyond proof of concept to reproducible clinical performance across patients and diseases. He discusses the importance of patient selection, tissue specificity, and matching editing efficiency to biological thresholds, and much more. Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

The use of biotherapies has surged in recent years, creating new challenges and opportunities for pharmacy. In this episode, three experienced pharmacists in the world of biotherapeutic drugs will review key considerations for working with these agents. Their discussion will cover biosafety review processes and how to develop the structure to support ongoing management of biotherapeutics. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

A non-invasive Alzheimer's therapy is moving closer to patients, and it could reshape how brain health is treated. In this episode, Christian Howell, CEO of Cognito Therapeutics, joins Saul live at DeviceTalks Boston to discuss how the company is advancing a novel Alzheimer's therapy that uses sensory stimulation through light, sound, and touch. He shares insights from Cognito's HOPE study, the largest non-pharmacologic clinical trial in neurodegenerative disease, involving 673 participants across 70 sites. Christian explains why a strong evidence strategy is essential not only for regulatory approval but also for reimbursement, clinical adoption, and patient access. He also reflects on leadership lessons centered on service, humility, humor, and the importance of aligning stakeholders across the healthcare ecosystem to improve Alzheimer's care. Tune in to hear how Christian Howell and Cognito Therapeutics are working to bring new hope, stronger evidence, and a more accessible path forward for Alzheimer's patients and families! Resources: Connect with and follow Christian Howell on LinkedIn. Follow Cognito Therapeutics on LinkedIn and explore their website.

Jake Becraft is the CEO and co-founder of Strand Therapeutics, a company building one of the most advanced programmable genetic medicine platforms in biotechnology. Under his leadership, Strand is redefining what RNA medicines can do by enabling cell-selective targeting and therapeutic payload delivery inside the body, unlocking a new class of precision genetic therapies.This episode is brought to you by:Helix Sleep premium mattresses: HelixSleep.com/Tim (20% off any purchase) Incogni, which automatically removes your personal data from the web, helping shield you from fraud, scams, and identity theft: Incogni.com/Tim (use code TIM at checkout and get 60% off an annual plan)*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adapting to regulatory inconsistencies around rare disease drug approval frameworks in the U.S. and Europe.     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

A conversation with Dr. Babak Kateb Find the video of this conversation at https://youtu.be/GbnIhjO_Af0 Find more at https://www.worldbrainmapping.org/